Clinical trials: PICS

ICU Acquired Weakness

Evaluation of FDY-5301 in Major Trauma Patients in ICU

• Terminated
• Age: 18 to 75 years
• Phase 2
• Results posted

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of FDY-5301 compared to placebo in major trauma ICU patients at risk of intensive care unit acquired weakness (ICUAW)

Trial name

NCT04430283

Testing

FDY-5301

Where

5 sites in United States

Volunteers

8 people

Sponsor

Faraday Pharmaceuticals, Inc.